Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BlueRock Therapeutics
Biotech
Stylus outlines next-gen gene editing mission with $85M in hand
The 40-person company is led by CEO Emile Nuwaysir, Ph.D., former CEO of Bayer’s cell therapy outfit BlueRock Therapeutics.
Gabrielle Masson
May 13, 2025 7:00am
UK cell programming biotech lays off 25% of staff
Mar 19, 2025 3:05pm
Bayer moves allogeneic cell therapy into ph. 3 Parkinson's trial
Jan 13, 2025 2:30am
Bayer preps phase 2 after Parkinson's cell therapy scores win
Aug 28, 2023 2:00am
Bayer-owned BlueRock cuts 12% of staff as pipeline contracts
Aug 17, 2023 3:00pm
Bayer's acting BD chief lobbies for the job by making deals
May 24, 2023 3:00am
